Dextrorphan Amino Acid Ester Stereoisomer Conjugates with Improved Bioavailability

The USPTO published a patent application (US20260098013A1) disclosing a class of compounds comprising amino acid ester conjugates of dextrorphan, wherein the amino acids are diastereomerically pure. The application covers methods of manufacturing these compounds and pharmaceutical compositions containing them, along with methods of treating diseases or conditions using the conjugates.

Pharmaceutical manufacturers and drug developers should monitor this application for potential licensing opportunities or to assess freedom-to-operate implications. The use of diastereomerically pure amino acids to improve dextrorphan bioavailability represents a novel approach that may offer competitive advantages in drug development. Parties developing opioid alternatives, neuroprotective agents, or related compounds should evaluate their IP positions relative to this application.